The DOI matches its Crossref record.
Insulin insulated: barriers to competition and affordability in the United States insulin market
Open accessAbstract
Insulin prices in the United States are skyrocketing. In addition to several challenges common to high-priced prescription drugs, insulin faces several unique legal, regulatory, and practical challenges to increasing access and affordability. Despite the fact that insulin was developed almost 100 years ago, the insulin market is dominated by only three companies and there continue to be no biosimilar competitors in the United States. Unlike many high-priced prescription drugs, insulin has been insulated from competition for years. This article examines the barriers to competition in the insulin market, considering the challenges surrounding regulatory approval, interchangeability, trade secrets, and anticompetitive behavior. Further, this article discusses the potential and limitations of various legislative proposals to address access to insulin. In doing so, this article attempts to explain why there is such limited competition in the insulin market and identifies issues specific to the insulin market for lawmakers to consider in developing proposals to address access to affordable insulin in the United States.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Currently, GLP1-RAs are manufactured by three main providers, and this oligopoly likely contributes to the elevated costs, as seen with other pharmaceutical agents.107”
From The societal implications of using glucagon-like peptide-1 receptor agonists for the treatment of obesity (2025) · cites this paper as [107]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Currently, GLP1-RAs are manufactured by three main providers, and this oligopoly likely contributes to the elevated costs, as seen with other pharmaceutical agents.107”
From The societal implications of using glucagon-like peptide-1 receptor agonists for the treatment of obesity (2025) · cites this paper as [107]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Still being checked.
Cited by
Sorted by citations
The Centenary of the Discovery of Insulin: An Update on the Quest for Oral Delivery
Brayden, D. J. (2021) · Frontiers in Drug Delivery · doi:10.3389/fddev.2021.726675 · Cited by 25
Yuan, J., Li, M., Jiang, X., & Lu, K. (2024) · BMJ Global Health · doi:10.1136/bmjgh-2023-014489 · Cited by 18
Scragg, J., Koutoukidis, D. A., Dirksen, C., Heitmann, B. L., & Jebb, S. A. (2025) · Med · doi:10.1016/j.medj.2025.100805 · Cited by 16
Santos, D. (2023) · Environmental Innovation and Societal Transitions · doi:10.1016/j.eist.2023.100783 · Cited by 12
Copper Oxide Electrochemical Deposition to Create Antiviral and Antibacterial Nanocoatings
Kusior, A., Mazurków, J., Jeleń, P., Bik, M., Raza, S., Wdowiak, M., Nikiforov, K., & Paczesny, J. (2024) · Langmuir · doi:10.1021/acs.langmuir.4c00642 · Cited by 11
Panda, C., Kumar, S., Gupta, S. K., & Pandey, L. M. (2024) · Critical Reviews in Biotechnology · doi:10.1080/07388551.2024.2387167 · Cited by 8
Market Shaping and Market Access in the Global Vaccines Market: Approaches for the FuturePreprint
Sampath, P. G. (2021) · SSRN Electronic Journal · doi:10.2139/ssrn.3945668 · Cited by 6
Does Insulin Price Reduction Suggest a Path Forward for Lowering Drug Costs?
Brennan, T. A. (2023) · JAMA · doi:10.1001/jama.2023.5025 · Cited by 4
CalRx Biosimilar Insulin: California’s Initiative to Enter the Insulin Market
Feldman, R. (2023) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2023.3280 · Cited by 4
Enhancing insulin supply chain resilience: A critical importance for diabetes management
Haji, M. (2023) · Global Journal of Obesity Diabetes and Metabolic Syndrome · doi:10.17352/2455-8583.000063 · Cited by 3
Rai, A., Nam, Y. H., Mendelsohn, A. B., Marshall, J. H., McDermott, C. L., Toh, S., & Lockhart, C. M. (2023) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2023.29.7.842 · Cited by 2
Insulin’s Legacy: A Century of Breakthroughs and Innovation
Hadid, S. A., Zhang, E., Frishman, W. H., & Brutsaert, E. F. (2024) · Cardiology in Review · doi:10.1097/crd.0000000000000680 · Cited by 2
Prandial Insulins: A Person-Centered Choice
Attri, B., Nagendra, L., Dutta, D., Shetty, S., Shaikh, S. S., Kalra, S., & Bhattacharya, S. (2024) · Current Diabetes Reports · doi:10.1007/s11892-024-01540-8 · Cited by 2
Discussion Paper on the Interplay between Patents and Trade Secrets in Medical TechnologiesPreprint
Aplin, T. F., & Liddicoat, J. (2023) · SSRN Electronic Journal · doi:10.2139/ssrn.4606923 · Cited by 2
Chiang, Y.-Y., dosReis, S., Rochester-Eyeguokan, C. D., & Onukwugha, E. (2024) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2024.30.11.1288 · Cited by 1
The case for primary prevention of obesity in the era of GLP-1 therapies
Holm, S., Tena‐Sempere, M., Koutsouris, D., Dedoussis, G. V., Wagner, K., Martinez, S. A., Froguel, P., Bohn, T., Oliveira, P. J., Lakerveld, J., et al. (2026) · The Lancet Regional Health - Europe · doi:10.1016/j.lanepe.2026.101679 · Cited by 1
Insulin Patient Assistance Programs and Protected Heath Information
Karakousis, C. P., Polito, F., Page, K., & Socal, M. P. (2026) · JAMA Network Open · doi:10.1001/jamanetworkopen.2026.11849 · Cited by 1
New Insulins, Biosimilars, and Insulin Therapy
Danne, T., Heinemann, L., & Bolinder, J. (2022) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2022.2503 · Cited by 1
Hundred Years of Insulin: The Possibility of Development of Oral Dosage Form
Saha, A., Sultana, A., Yesmin, F., Akter, T., Sikder, M. A. A., Aktar, F., Chowdhury, J. A., Chowdhury, A. A., Kabir, S., & Amran, M. S. (2021) · Avicenna Journal of Pharmaceutical Research · doi:10.34172/ajpr.2021.15
McCallum, K. (2023) · Texas A&M Journal of Property Law · doi:10.37419/jpl.v9.i1.8
An Hebraic Alternative to Mind-Body Dualism
Olney, S. H. (2024) · Advances in healthcare information systems and administration book series · doi:10.4018/979-8-3693-0015-2.ch007
Tackling Insulin Affordability
Yang, Y. T. (2024) · doi:10.1002/9781394263752.ch3
Fair Negotiation Model with Applications to Ethical Therapeutic Drug Pricing
Lee, E. S., Hossain, S., & Zhang, R. (2024) · IEEE MIT Undergraduate Research Technology Conference (URTC) · doi:10.1109/urtc65039.2024.10937560
Todde, S. (2025) · The International Trade Journal · doi:10.1080/08853908.2025.2573288
Sklar, J., Harel, S., Lipska, K. J., Lukasik, J., Wilcox, A., Flynn, A., WEINZIMER, S. A., Suttiratana, S. C., & Nally, L. M. (2026) · Diabetic Medicine · doi:10.1111/dme.70313
Biosimilar insulin glargine: a solution for affordable and equitable diabetes care
Kumar, H., Gopal, J., Shamanna, P., Hasnani, D., Chavda, V., Prajapati, H. K., & Papaiya, H. V. (2026) · International Journal of Advances in Medicine · doi:10.18203/2349-3933.ijam20261888
Yu, M., Zhu, Y., Wei, J., Yao, H., Jing, Z., Wang, X., Tao, T., & Li, X. (2026) · Tropical Medicine & International Health · doi:10.1111/tmi.70192
Metadata
- Authors
- Knox, R.
- Affiliations
- Yale University (US)
- Corresponding author
- Knox, Ryan
- ORCID
- Knox, Ryan
- Venue
- Journal of Law and the Biosciences
- Publisher
- Oxford University Press (OUP)
- Published
- 2020-01
- Volume
- 7
- Issue
- 1
- Pages
- lsaa061-lsaa061
- ISSN
- 2053-9711 (ISSN-L)
- PMC
- PMC8249113
- OpenAlex
- W3160235632
- Cited by
- 27
- References
- 0
- Citations by year
- 2026: 5 · 2025: 2 · 2024: 9 · 2023: 7 · 2022: 1 · 2021: 3
- FWCI
- 2.34
- Type
- journal article
- Language
- en
- Open access
- diamond
- doi.org
- Licence
- Locations
- Journal of Law and the Biosciences (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- eScholarship (California Digital Library) (submittedVersion, cc-by-nc-nd)
- Funders
- Eli Lilly and Company
- Novo Nordisk
- Topics
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Pharmaceutical Economics and Policy
- Life Sciences › Immunology and Microbiology › Immunology › Biosimilars and Bioanalytical Methods
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Healthcare Policy and Management
- Keywords
- insulin, drug affordability, market competition, biosimilars, trade secrets, anticompetitive practices, regulatory approval, health care legislation, pharmaceutical market
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
